OQROGet OQRO Pro
Insider trade

Rein Therapeutics (RNTX)10% owner bought ~$6.6K

Voss Capital, 10% owner at Rein Therapeutics, bought ~$6.6K of Rein Therapeutics shares.

~$6.6K
Approx. value · 4,840 sh @ $1.37
322K
Holds after · shares reported
Traded
Oct 27, 2025
Filed
Oct 28, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 8, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  2. Oct 23, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  3. Oct 24, 2025Insider · Their first buy on record10% owner purchased ~$42K of RNTX shares in the open market
  4. Oct 27, 2025 · this disclosureInsider10% owner purchased ~$6.6K of RNTX shares in the open market

What came next

  1. Oct 27, 2025Insider10% owner purchased ~$127K of RNTX shares in the open market
  2. Oct 28, 2025Insider10% owner purchased ~$248K of RNTX shares in the open market
  3. Nov 14, 2025Insider10% owner purchased ~$128K of RNTX shares in the open market
  4. Dec 11, 2025Company filing · Form 8-K · Agreement endedEnded an important agreement
  5. Jan 15, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
  6. Feb 16, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 16, 2026, Manuel C. Alves Aivado, M.D., Ph.D., notified Rein Therapeutics, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), effective immediately.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Rein Therapeutics

OQRO holds no insider, Congress, fund or contract record for Rein Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RNTX page.

Other recent filings by Voss Capital, LP, 10% owner

The full history of Voss Capital, LP, 10% owner is on the profile page.

How this filing works

Other disclosures at Rein Therapeutics

Everything OQRO holds on this company is on its RNTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data